NeuroMetrix, Inc.
NeuroMetrix, Inc. (NURO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nuro · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
NeuroMetrix, Inc.You NURO | $9M | N/A | — | — |
 Apexigen, Inc. APGN | $10M | N/A | — | -$1.59 |
 China Jo-Jo Drugstores, Inc. CJJD | $10M | N/A | — | -$2.93 |
 Centogene N.V. CNTG | $9M | N/A | — | -$1.26 |
 CervoMed Inc. CRVO | $28M | N/A | — | -$2.98 |
 ETAO International Co., Ltd. ETAO | $10M | N/A | — | -$169.64 |
 Field Trip Health Ltd. FTRP | $10M | N/A | — | -$8.43 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for NeuroMetrix, Inc. (NURO) measures how much investors pay for each dollar of the company's trailing earnings. NURO's current PE ratio of N/A is calculated by dividing its stock price of $4.58 by its TTM earnings per share of —.
Frequently asked questions
NURO pe ratio · 6 questionsNURO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.58 and TTM EPS of —. Data sourced from Financial Modeling Prep via NURO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NeuroMetrix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09